Retatrutide
RM 230.00An investigational molecule that activates GIP, GLP-1 and glucagon receptors. It is being studied for obesity and metabolic outcomes.
Read more
An investigational molecule that activates GIP, GLP-1 and glucagon receptors. It is being studied for obesity and metabolic outcomes.
A triple-receptor agonist still in clinical development—not an approved medicine for general use.
People compare it with semaglutide and tirzepatide because it adds a glucagon pathway to GIP and GLP-1 activity.
Human trials are ongoing. Early results do not establish long-term safety, personal suitability or approval.
Online or ‘research use’ versions are not the same as a regulated clinical-trial product.
Not for under-18s to self-select. Pregnancy, breastfeeding, chronic illness, older age, or current medicines require individual professional review.

Retatrutide